The company's goal is to perform nonviral manufacturing of cell therapies within days instead of weeks. Kytopen's Flowfect technology utilizes electromechanical energy to introduce genetic material such as RNA, DNA, or CRISPR-Cas ribonucleoprotein to a variety of hard-to-transfect primary human cells.

The money, said Kytopen, is expected to speed the commercialization of the company's high-throughput automated platform that eliminates the complexity of gene editing and integrates discovery, development, and manufacturing into one nonviral delivery system.

The series A financing round was led by Northpond Ventures, with participation from investors that included The Engine, Horizon Ventures, and Mass Ventures, as well as Aldevron co-founders, and Alexandria Venture Investments.

Kytopen granted SBIR for nonviral NK cell gene editing platform
Kytopen has been awarded a Small Business Innovation Research (SBIR) grant from the U.S. National Institute of Allergy and Infectious Diseases to demonstrate...